FDA Approves Menveo
Novartis Gets US Approval for Menveo Meningitis Vaccine
BASEL, Switzerland -- Swiss drug maker Novartis AG said Monday that its meningitis vaccine Menveo has been approved for use in teenagers and adults by the U.S. Food and Drug Administration.
Menveo is a vaccine against four common types of bacterial meningitis, which affects between 1,000 and 3,000 people each year in the United States.
The U.S. regulator approved the drug for people between 11 and 55, Novartis said.
Bacterial meningitis causes swelling of the membrane that covers the brain or spinal cord and can lead to death within 48 hours.
Novartis said it is continuing clinical trials for the use of the vaccine in other age groups.
The drug received a positive recommendation from the European Union’s regulator in December, and Novartis says it expects full EU approval in the coming months.
Posted: February 2010
Related articles
- FDA Approves Menveo in a New Single-Vial Presentation to Help Prevent Disease Caused by Meningococcal Bacteria Serogroups A, C, Y, and W - October 17, 2022
- FDA Expands Age Indication for Menveo - August 2, 2013
- FDA Approves the Novartis Quadrivalent Meningococcal Conjugate Vaccine, Menveo, for Use in Children From 2 Years of Age - January 31, 2011
- Novartis Receives Complete Response Letter From The US Food And Drug Administration For Its Investigational Vaccine Menveo - July 1, 2009
Menveo (meningococcal conjugate vaccine) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
